Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19
Anshuman Chandra, Vaishali Gurjar, Imteyaz Qamar, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 12, pp. 4201-4211
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management
Peter Chinedu Agu, Celestine Azubuike Afiukwa, O.U. Orji, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 342
An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2
Jatin Sharma, Vijay Kumar Bhardwaj, Rahul Singh, et al.
Food Chemistry (2020) Vol. 346, pp. 128933-128933
Open Access | Times Cited: 183
Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight into nuclease specificity and dynamics
Monica C. Pillon, Meredith N. Frazier, Lucas Dillard, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 114
Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors
Sk. Abdul Amin, Kalyan Ghosh, Shovanlal Gayen, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 13, pp. 4764-4773
Open Access | Times Cited: 101
Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus
Akinwunmi Oluwaseun Adeoye, Babatunde Joseph Oso, Ige Olaoye, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 10, pp. 3469-3479
Open Access | Times Cited: 80
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease
Berta Canal, Ryo Fujisawa, Allison W. McClure, et al.
Biochemical Journal (2021) Vol. 478, Iss. 13, pp. 2465-2479
Open Access | Times Cited: 59
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2
Kaifu Gao, Rui Wang, Jiahui Chen, et al.
Chemical Reviews (2022) Vol. 122, Iss. 13, pp. 11287-11368
Open Access | Times Cited: 58
Inhibition of nonstructural protein 15 of SARS‐CoV‐2 by golden spice: A computational insight
Rahul Singh, Vijay Kumar Bhardwaj, Rituraj Purohit
Cell Biochemistry and Function (2022) Vol. 40, Iss. 8, pp. 926-934
Open Access | Times Cited: 51
Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer’s disease
Rohit Shukla, Tiratha Raj Singh
Journal of Biomolecular Structure and Dynamics (2019) Vol. 38, Iss. 1, pp. 248-262
Closed Access | Times Cited: 56
Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CLpro)
Shruti Koulgi, Vinod Jani, Mallikarjunachari Uppuladinne V N, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 15, pp. 5735-5755
Open Access | Times Cited: 53
In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19
Vipul Kumar, Sudhakar Kancharla, Manoj Kumar Jena
VirusDisease (2021) Vol. 32, Iss. 1, pp. 29-37
Open Access | Times Cited: 53
Metabolic profiling and antidiabetic potential of Oedogonium angustistomum, Ulothrix variabilis, and Mougeotia pulchella and their peptides targeting α-amylase and α-glucosidase: In vitro and in silico approaches
Sruthy Elsa Shibu, Edathiruthi Kottukkal Chandran Baiju, Singamoorthy Amalraj, et al.
International Journal of Biological Macromolecules (2025), pp. 140877-140877
Closed Access
Cancer therapy and treatments during COVID-19 era
Shaw M. Akula, Stephen L. Abrams, Linda S. Steelman, et al.
Advances in Biological Regulation (2020) Vol. 77, pp. 100739-100739
Open Access | Times Cited: 43
Interferon-inducer antivirals: Potential candidates to combat COVID-19
Ashkan Bagheri, Seyed Mohammad Iman Moezzi, Pouria Mosaddeghi, et al.
International Immunopharmacology (2020) Vol. 91, pp. 107245-107245
Open Access | Times Cited: 39
Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2
Parth Sarthi Sen Gupta, Satyaranjan Biswal, Dipankar Singha, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 14, pp. 5327-5333
Closed Access | Times Cited: 37
Structure-based drug designing towards the identification of potential anti-viral for COVID-19 by targeting endoribonuclease NSP15
Anantha Krishnan Dhanabalan, Gopalakrishnan Sangeetha, S. Vajravijayan, et al.
Informatics in Medicine Unlocked (2020) Vol. 20, pp. 100392-100392
Open Access | Times Cited: 34
Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology
Claudine E. Bayles, Danielle E. Hale, Ali Konieczny, et al.
Toxicology and Applied Pharmacology (2022) Vol. 459, pp. 116362-116362
Open Access | Times Cited: 19
COVID-19 Biogenesis and Intracellular Transport
Alexander A. Mirоnоv, M.A. Savin, Galina V. Beznoussenko
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4523-4523
Open Access | Times Cited: 11
MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
Olanrewaju Ayodeji Durojaye, Nkwachukwu Oziamara Okoro, Arome Solomon Odiba, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Nucleic Acid-Sensing Pathways During SARS-CoV-2 Infection: Expectations versus Reality
Bushra Mdkhana, Narjes Saheb Sharif‐Askari, Rakhee K. Ramakrishnan, et al.
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 199-216
Open Access | Times Cited: 26
Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications
Biswajit Naik, Venkata Satish Kumar Mattaparthi, Nidhi Gupta, et al.
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 19, pp. 9543-9567
Open Access | Times Cited: 25
Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods
Anshuman Chandra, Vaishali Gurjar, Mohammad Z. Ahmed, et al.
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 12, pp. 5507-5514
Closed Access | Times Cited: 23
Structure-based inhibitor screening of natural products against NSP15 of SARS-CoV-2 revealed thymopentin and oleuropein as potent inhibitors
Ramachandran Vijayan, Samudrala Gourinath
Journal of Proteins and Proteomics (2021) Vol. 12, Iss. 2, pp. 71-80
Open Access | Times Cited: 21
A survey on computational methods in discovering protein inhibitors of SARS-CoV-2
Qiaoming Liu, Jun Wan, Guohua Wang
Briefings in Bioinformatics (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 20
An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery
Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel, et al.
Current Topics in Medicinal Chemistry (2021) Vol. 21, Iss. 7, pp. 571-596
Closed Access | Times Cited: 18
Page 1 - Next Page

Scroll to top